WillItSurvive
Medical technology and health companies · United States

Insulet

insulet.com ↗

Insulet makes the Omnipod, a tubeless wearable insulin pump for diabetes patients.

Defensible for now
Assessed 22 July 2026 · Evidence as of 22 July 2026
Real protection, with named pressure against it.
On the recordSince 22 July 2026 · Checkable from August 5, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report
The call

Insulet keeps growing fast on Omnipod 5, but two manufacturing corrections and a lawsuit sit next to rivals finally shipping their own tubeless pumps.

Insulet sells Omnipod, a small wireless pump that delivers insulin without tubes, and has built a large base of patients and insurance coverage. The company faces real pressure from Tandem Diabetes, which launched its own patch pump called Mobi in early 2024, and from Beta Bionics, whose artificial pancreas system is growing fast. What matters most right now is whether Insulet can fix its manufacturing problems (it recalled millions of pods in 2026 and faces a lawsuit), because a third major recall or a warning from regulators could prove that the company's quality systems are broken, not just bumpy.

Why
01
AI pressure: None apparent. The algorithm inside Omnipod 5 automates dosing decisions, but this helps Insulet sell pumps rather than replacing the company. Could AI do the core job? Unlikely.
02
Bigger players: Tandem Diabetes Care (Mobi) and Beta Bionics (iLet). Tandem shipped its own tubeless-style patch pump Mobi and Beta Bionics grew 36% in a quarter, both chipping at what made Omnipod different. Could a giant copy it? No, they are blocked.
03
What protects it. FDA clearances, insurance contracts, and years of patient habit make switching pumps slow even when rivals catch up on features.
What would change this call
Insulet issues a third Medical Device Correction on Omnipod pods within 2026. Would suggest a manufacturing pattern rather than a contained bruise.
FDA issues a warning letter or consent decree tied to the Acton facility. Would show regulatory escalation constraining production, not just voluntary corrections.
Tandem or Beta Bionics report installed-base or revenue growth outpacing Insulet in H2 2026. Would indicate measurable attrition of Insulet's customer base to tubeless rivals.
Key numbers
  • FY2025 revenue $2.708B, up 31% YoY (2026-02-18)
  • Q1 2026 revenue $761.7M, up 33.9% YoY (2026-05-06)
  • Two pod corrections in 2026 covering ~7M pods (2026-05-01)
Named risks
  • Active securities class action over manufacturing misrepresentation, lead plaintiff deadline Aug 31 2026. Severity: high
  • Two 2026 Medical Device Corrections affecting ~7M pods raise chance of FDA enforcement action. Severity: high
  • Tandem Mobi and Beta Bionics eroding Insulet's tubeless differentiation. Severity: medium
  • Multiple sell-side price target cuts in mid-2026 signal reassessed valuation after safety disclosures. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Tandem Diabetes Caregaining onShipped Mobi patch pump Feb 2024; FY2025 revenue ~$2.07B, 22% growth
Beta Bionicsgaining oniLet Bionic Pancreas grew 36% in Q1 2025, payer coverage reached ~12M insured patients by June 2025
MedtroniccontestingHolds ~53% of broader insulin pump market as of Jan 2026 but remains tubed, slow to pivot to tubeless
Questions people ask
Is Insulet profitable in 2026?
Yes. Insulet posted Q1 2026 revenue of $761.7 million, up 33.9% year over year, with adjusted EPS of $1.42 beating consensus estimates of $1.14 to $1.19, reported May 6, 2026. Full-year 2026 guidance calls for 21 to 23% total revenue growth.
Is Insulet facing lawsuits over Omnipod defects?
Yes. A securities class action, Hu v. Insulet Corporation, No. 26-cv-13062 in the District of Massachusetts, alleges misrepresentation about manufacturing quality tied to two 2026 voluntary Medical Device Corrections. The lead plaintiff deadline is August 31, 2026.
Who is Insulet's biggest competitor?
Tandem Diabetes Care is the closest rival, having shipped its tubeless-style Mobi patch pump in February 2024 and reporting about $2.07 billion revenue with 22% growth. Medtronic still leads the broader pump market with roughly 53% share, though its platform is tubed.
Could AI replace Insulet's Omnipod?
Not directly. Omnipod's core value is FDA-regulated hardware and an automated insulin delivery algorithm; AI can enhance analytics layers like Omnipod Discover, but physical pod manufacturing, CGM integrations, and payer relationships remain hardware-anchored moats as of June 2026.
Has Insulet had product recalls in 2026?
Yes. Insulet issued two voluntary Medical Device Corrections in 2026, on March 12 and May 26, for a tubing and cannula defect affecting Omnipod 5, DASH, and Eros pods, cumulatively covering an estimated 7 million pods, each triggering stock drops of 6.88% and 5.07% respectively.
Is it safe to invest in Insulet stock right now?
Insulet's stock fell from a 52-week high of $354.88 to roughly $146 to $161 by July 22, 2026, amid manufacturing corrections and litigation, even as market cap held around $11.3 to $11.6 billion and Q1 2026 revenue grew 33.9% year over year.
Timeline
  • 2026-07-06Insulet launches Omnipod 5 and Omnipod Discover in Spain
  • 2026-07-01Jonathan Mazelsky joins Insulet board of directors
  • 2026-06-03Enhanced Omnipod 5 algorithm rolls out in U.S., adds Libre 3 Plus support
  • 2026-05-26Second 2026 Medical Device Correction issued, stock falls 5.07%
  • 2026-05-06Q1 2026 results: revenue $761.7M, up 33.9% YoY, EPS $1.42
  • 2026-03-12First 2026 Medical Device Correction issued, stock falls 6.88%
  • 2026-02-18FY2025 results: revenue $2.708B, up 31% YoY, 10th year of 20%+ growth
  • 2026-02-05Omnipod 5 launches in Middle East (Saudi Arabia, Kuwait, Qatar, UAE)
  • 2024-02Tandem Diabetes Care launches Mobi patch pump
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
AbridgeSeegeneOlympus Corporation
More in Medical technology and health companies →
Sources